|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2000-2-17
|
|
pubmed:abstractText |
The Hoosier Oncology Group has previously reported the results of its phase II trial of the combination of cisplatin plus gemcitabine. In that study of 27 assessable patients with advanced or metastatic non-small-cell lung cancer (NSCLC), the response rate was 33%, with a median survival of 8.4 months. Based on such favorable results, the Hoosier Oncology Group designed this randomized phase III study of gemcitabine plus cisplatin compared with cisplatin alone in chemotherapy-naive patients with advanced NSCLC.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:CormierYY,
pubmed-author:DenhamCC,
pubmed-author:EinhornL HLH,
pubmed-author:GatzemeierUU,
pubmed-author:GregorAA,
pubmed-author:ManegoldCC,
pubmed-author:MattsonKK,
pubmed-author:NemunaitisJJ,
pubmed-author:NguyenBB,
pubmed-author:NiyikizaCC,
pubmed-author:PalmerM CMC,
pubmed-author:SandlerA BAB,
pubmed-author:von PawelJJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
122-30
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10623702-Adult,
pubmed-meshheading:10623702-Aged,
pubmed-meshheading:10623702-Aged, 80 and over,
pubmed-meshheading:10623702-Analysis of Variance,
pubmed-meshheading:10623702-Antimetabolites, Antineoplastic,
pubmed-meshheading:10623702-Antineoplastic Agents,
pubmed-meshheading:10623702-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10623702-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:10623702-Cisplatin,
pubmed-meshheading:10623702-Deoxycytidine,
pubmed-meshheading:10623702-Female,
pubmed-meshheading:10623702-Humans,
pubmed-meshheading:10623702-Lung Neoplasms,
pubmed-meshheading:10623702-Male,
pubmed-meshheading:10623702-Middle Aged,
pubmed-meshheading:10623702-Proportional Hazards Models,
pubmed-meshheading:10623702-Survival Analysis,
pubmed-meshheading:10623702-Time Factors
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.
|
|
pubmed:affiliation |
Hoosier Oncology Group, The Walther Cancer Institute, Department of Medicine, Indiana University, Indianapolis, USA. asandler@iupuie.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
